Adagene (ADAG) Competitors $2.50 +0.11 (+4.60%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.62 +0.13 (+5.00%) As of 09/9/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. AUTL, KMDA, AURA, YMAB, VIGL, AQST, OLMA, RCKT, FULC, and ABEOShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Autolus Therapeutics (AUTL), Kamada (KMDA), Aura Biosciences (AURA), Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), Fulcrum Therapeutics (FULC), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Autolus Therapeutics Kamada Aura Biosciences Y-mAbs Therapeutics Vigil Neuroscience Aquestive Therapeutics Olema Pharmaceuticals Rocket Pharmaceuticals Fulcrum Therapeutics Abeona Therapeutics Adagene (NASDAQ:ADAG) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations. Is ADAG or AUTL more profitable? Adagene's return on equity of 0.00% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Autolus Therapeutics N/A -56.18%-29.61% Which has more volatility & risk, ADAG or AUTL? Adagene has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Which has stronger earnings and valuation, ADAG or AUTL? Adagene has higher earnings, but lower revenue than Autolus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K1,178.25-$33.42MN/AN/AAutolus Therapeutics$29.93M12.18-$220.66M-$0.84-1.63 Do institutionals & insiders have more ownership in ADAG or AUTL? 9.5% of Adagene shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ADAG or AUTL? Adagene presently has a consensus price target of $7.00, suggesting a potential upside of 180.00%. Autolus Therapeutics has a consensus price target of $9.12, suggesting a potential upside of 565.69%. Given Autolus Therapeutics' higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ADAG or AUTL? In the previous week, Adagene had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 5 mentions for Adagene and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 1.67 beat Adagene's score of 0.49 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryAutolus Therapeutics beats Adagene on 7 of the 13 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.64M$3.17B$5.83B$10.00BDividend YieldN/A2.28%5.28%4.53%P/E RatioN/A21.3475.6926.28Price / Sales1,178.25471.32544.78188.18Price / CashN/A45.5837.2059.76Price / Book2.1910.0511.506.41Net Income-$33.42M-$53.33M$3.28B$270.56M7 Day Performance14.68%1.39%1.42%3.13%1 Month Performance15.21%11.91%11.28%9.74%1 Year Performance-17.49%13.21%59.03%28.17% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene3.2246 of 5 stars$2.50+4.6%$7.00+180.0%-13.8%$112.64M$100K0.00260High Trading VolumeAUTLAutolus Therapeutics3.2675 of 5 stars$1.50-4.5%$9.12+508.0%-66.5%$399.21M$10.12M-1.79330Positive NewsKMDAKamada3.9958 of 5 stars$6.92-1.4%$13.00+87.9%+34.1%$397.93M$160.95M20.35360Positive NewsShort Interest ↑AURAAura Biosciences2.321 of 5 stars$6.26-2.6%$22.00+251.4%-19.7%$388.87MN/A-3.1950Positive NewsYMABY-mAbs Therapeutics2.7529 of 5 stars$8.55+0.1%$9.62+12.5%-35.8%$388.50M$87.68M-17.10150Positive NewsShort Interest ↓VIGLVigil Neuroscience1.3298 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340AQSTAquestive Therapeutics2.9699 of 5 stars$3.77-1.6%$10.14+169.0%+6.2%$375.96M$57.56M-5.39160News CoverageAnalyst ForecastInsider TradeOLMAOlema Pharmaceuticals2.5123 of 5 stars$5.46-1.1%$24.00+339.6%-40.4%$374.74MN/A-2.7670Positive NewsRCKTRocket Pharmaceuticals4.8634 of 5 stars$3.28-2.1%$16.73+410.2%-83.7%$353.92MN/A-1.31240Positive NewsFULCFulcrum Therapeutics0.9234 of 5 stars$6.48-2.6%$7.57+16.8%-16.1%$350.51M$80M-5.31100News CoveragePositive NewsABEOAbeona Therapeutics4.3942 of 5 stars$6.83-0.7%$19.50+185.5%+21.5%$350.23M$3.50M9.7690 Related Companies and Tools Related Companies AUTL Competitors KMDA Competitors AURA Competitors YMAB Competitors VIGL Competitors AQST Competitors OLMA Competitors RCKT Competitors FULC Competitors ABEO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
